Patients
bleeding, hemoptysis, trauma, cancer, malignancy, fracture, toxicity, diabetes, infection, psychiatric, skin cancer, comorbid illness, renal cell cancer, hypertension, ulcer, gastrointestinal abnormalities, Cancer
BLEEDING, SECOND MALIGNANCY, CANCER, DELAYED HYPERSENSITIVITY REACTION, METASTATIC DISEASE, DIABETES, INFECTION, REMISSION, SKIN CANCER, RENAL CELL CANCER, HYPERTENSION, ULCER, BLEEDING DIATHESIS, CANCER
From 2011 to 2014, patients were recruited from the oncology clinics at the Dartmouth Cancer Center and the University of Vermont Cancer Center. Study inclusion criteria were: histologically proven renal cell cancer with measurable metastatic disease according to RECIST 1.1Patients were excluded from the study if they had a concomitant second malignancy except for non‐melanoma skin cancer or non‐invasive cancer, or a prior history of invasive malignancy within 5 years of complete remission. Other exclusion criteria included significant comorbid illness such as uncontrolled diabetes, hypertension or active infection; clinically significant gastrointestinal abnormalities; prolongation of corrected QT interval (QTc) >480 milliseconds; history of any cardiovascular conditions within the past 12 months; prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non‐healing wound, fracture, or ulcer; any serious and/or unstable pre‐existing medical, psychiatric, or other conditions that could interfere with subject's safety, obtaining informed consent, or compliance with the study; evidence of active bleeding or bleeding diathesis; ongoing toxicity from prior anti‐cancer therapy that is >grade 1 and/or that is progressing in severity; previous treatment with either sunitinib or temsirolimus, or known immediate or delayed hypersensitivity reaction to drugs chemically related to sunitinib or temsirolimus; and hemoptysis within 6 weeks of first dose of study drug.